What is the clinical evidence from this study?

Study design: null. Population: Type 2 Diabetes Mellitus (T2DM) (n=9901). Intervention: Dulaglutide vs. Placebo. Primary outcome: Three-point major adverse cardiac events (MACE) (RR 0.88, 95% CI null, p=null).

What question did this study set out to answer?

The article aims to summarize the advancements made in cardiovascular prevention over the past year.

February 2, 2026Srce i krvni sudovi0 citationsOpen Access

The year in cardiology: Cardiovascular prevention

KRKausik RayNIHR Imperial Biomedical Research Centre ULULRICH LAUFSPreventive Cardiology FCFrancesco CosentinoKarolinska University Hospital

Key Result

Dulaglutide resulted in a significant 12% relative risk reduction in MACE compared to placebo over a median follow-up of 5.4 years.

Key Points

The article aims to summarize the advancements made in cardiovascular prevention over the past year.
Review of recent literature on cardiovascular prevention strategies
Analysis of new guidelines and recommendations
Evaluation of clinical practices in cardiovascular disease management
Identification of new risk factors affecting cardiovascular health
Evidence supporting lifestyle changes as effective prevention methods
Updates on pharmacological treatments for cardiovascular disease prevention

Study Design

Type

null (n=9,901)

Blinding

null

Randomization

null

PICO

Population

Type 2 Diabetes Mellitus (T2DM) (n=9,901)

Intervention / Comparator

Dulaglutide vs Placebo (Once weekly subcutaneous)

Primary Outcome

Three-point major adverse cardiac events (MACE) — RR 0.88 (null), p=null

Main Result

Effect estimate: RR 0.88 (95% CI null)

Absolute Event Rate: 12% vs 13.4%

p-value: p=null

Abstract

The article does not contain abstract.

问 AI

Bookmark

View Full Paper

问 AI

Bookmark

View Full Paper

Cite This Study

Ray et al. (Tue,) conducted a null in Type 2 Diabetes Mellitus (T2DM) (n=9,901). Dulaglutide vs. Placebo was evaluated on Three-point major adverse cardiac events (MACE) (RR 0.88, 95% CI null, p=null). Dulaglutide resulted in a significant 12% relative risk reduction in MACE compared to placebo over a median follow-up of 5.4 years.

synapsesocial.com/papers/6980fecbc1c9540dea8113d6 https://doi.org/https://doi.org/10.5937/siks1902107r